Bailard Inc. lifted its stake in PetIQ, Inc. (NASDAQ:PETQ – Free Report) by 53.0% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 15,300 shares of the company’s stock after purchasing an additional 5,300 shares during the quarter. Bailard Inc.’s holdings in PetIQ were worth $338,000 as of its most recent SEC filing.
A number of other hedge funds have also bought and sold shares of the stock. Raymond James & Associates purchased a new position in PetIQ in the 4th quarter worth $209,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in PetIQ during the 4th quarter worth approximately $177,000. Swiss National Bank acquired a new stake in PetIQ during the 4th quarter valued at approximately $1,080,000. Natixis Advisors L.P. increased its stake in shares of PetIQ by 10.2% in the fourth quarter. Natixis Advisors L.P. now owns 12,038 shares of the company’s stock worth $237,000 after acquiring an additional 1,113 shares during the period. Finally, LSV Asset Management purchased a new position in shares of PetIQ during the fourth quarter worth $849,000. Institutional investors and hedge funds own 94.99% of the company’s stock.
Insiders Place Their Bets
In other news, Director Scott Huff sold 12,117 shares of the stock in a transaction dated Wednesday, June 12th. The stock was sold at an average price of $22.19, for a total value of $268,876.23. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 9.62% of the stock is owned by company insiders.
Wall Street Analysts Forecast Growth
Check Out Our Latest Research Report on PetIQ
PetIQ Stock Performance
Shares of PetIQ stock opened at $30.50 on Tuesday. The company has a debt-to-equity ratio of 1.68, a current ratio of 2.58 and a quick ratio of 1.68. The stock has a market capitalization of $907.44 million, a price-to-earnings ratio of 138.64 and a beta of 1.71. The business has a 50-day moving average of $24.29 and a 200 day moving average of $20.41. PetIQ, Inc. has a 12 month low of $15.09 and a 12 month high of $30.68.
PetIQ (NASDAQ:PETQ – Get Free Report) last released its earnings results on Wednesday, August 7th. The company reported $0.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.50 by $0.20. PetIQ had a return on equity of 18.75% and a net margin of 1.20%. The firm had revenue of $328.90 million during the quarter, compared to analyst estimates of $330.14 million. During the same period last year, the business posted $0.37 earnings per share. PetIQ’s revenue was up 4.6% compared to the same quarter last year. As a group, sell-side analysts forecast that PetIQ, Inc. will post 1.12 earnings per share for the current year.
PetIQ Company Profile
PetIQ, Inc operates as a pet medication and wellness company in the United States and internationally. It operates in two segments, Products and Services. The company offers Rx pet medications, which sells flea and tick control, heartworm preventatives, arthritis, thyroid, diabetes and pain treatments, antibiotics, and other specialty medications; and develops and manufactures its own proprietary value-branded products, as well as third-party branded products for dogs and cats.
Read More
- Five stocks we like better than PetIQ
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- QuantumScape Pulls Back After July Surge: Is It Ready to Rebound?
- Want to Profit on the Downtrend? Downtrends, Explained.
- Workday Stock Perks Up on Results; New Highs Possible This Year
- 5 Top Rated Dividend Stocks to Consider
- CAVA Stock Surges on Q2 Beat: Is It the Next Chipotle?
Want to see what other hedge funds are holding PETQ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PetIQ, Inc. (NASDAQ:PETQ – Free Report).
Receive News & Ratings for PetIQ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetIQ and related companies with MarketBeat.com's FREE daily email newsletter.